Covestor’s Viridian Therapeutics VRDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$0 Sell
17
-12
-41% -$256 ﹤0.01% 2876
2026
Q2
$1K Buy
29
+24
+480% +$387 ﹤0.01% 2380
2026
Q1
$0 Hold
5
– – ﹤0.01% 2815
2025
Q4
$0 Hold
5
– – ﹤0.01% 2782
2025
Q3
$0 Hold
5
– – ﹤0.01% 2823
2025
Q2
$0 Hold
5
– – ﹤0.01% 2802
2025
Q1
$0 Hold
5
– – ﹤0.01% 2770
2024
Q4
$0 Sell
5
-2
-29% – ﹤0.01% 2787
2024
Q3
$0 Sell
7
-1
-13% – ﹤0.01% 2816
2024
Q2
$0 Buy
8
+4
+100% – ﹤0.01% 2804
2024
Q1
$0 Sell
4
-1
-20% – ﹤0.01% 2791
2023
Q4
$0 Hold
5
– – ﹤0.01% 2770
2023
Q3
$0 Buy
5
+2
+67% – ﹤0.01% 2763
2023
Q2
$0 Hold
3
– – ﹤0.01% 2700
2023
Q1
$0 Buy
+3
New – ﹤0.01% 2634

Other funds holding VRDN

Covestor's VRDN Position: Q3 2026 in Review

Covestor reduced its Viridian Therapeutics (VRDN) stake by 41% in Q3 2026, selling an estimated $256 and leaving 17 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2876.

Covestor first reported a position in VRDN in Q1 2023 and has held it in 15 quarters since. The position peaked at $1K in Q2 2026. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • Covestor held 17 shares of Viridian Therapeutics worth $0 as of Q3 2026.
  • Covestor sold 12 Viridian Therapeutics shares in Q3 2026, an estimated $256.
  • Viridian Therapeutics made up ﹤0.01% of Covestor's portfolio in Q3 2026, its #2876 holding.
  • Covestor first reported a position in Viridian Therapeutics in Q1 2023 and has held it in 15 quarters since.
  • Covestor's Viridian Therapeutics position peaked at $1K in Q2 2026.
  • 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.